Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 20, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification regarding shareholding changes within a specific employee retirement plan and does not contain financial performance data.
Material Changes
The filing details changes in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan") due to fund movements:
- December 15, 2005: Holdings decreased from 18,453,028 to 18,428,145 ADRs at an average price of $50.68.
- December 16, 2005: Holdings increased from 18,428,145 to 18,459,062 ADRs at an average price of $50.65.
These transactions were notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document focuses solely on the mechanics of the retirement plan's share adjustments.
Important Facts for Investors
- The Plan is a discretionary fund where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries.
- Two directors, Dr. J P Garnier and Dr. T Yamada, are potentially interested in the shares held in the fund in the same manner as other employees.
- The net change in the Plan's holdings over the two-day period was an increase of 5,934 ADRs.
- This filing does not represent a change in the company's operational strategy or financial health.